CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, obesity and hypothyroidism.
Hangzhou Polymed Biopharmaceuticals Inc. has synthesized crystalline forms of compounds acting as FLT3 (FLK2/STK1) and interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, neurological and inflammatory disorders.
Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
Inherited retinal diseases (IRDs) are a group of monogenic disorders caused by mutations in more than 280 genes, and are characterized by progressive degeneration of photoreceptor cells in the retina.
Researchers from Shenyang Pharmaceutical University and affiliated organizations have detailed the discovery and preclinical characterization of novel reversible lysine-specific demethylase 1 (LSD1) inhibitors as candidates for acute myeloid leukemia (AML) therapy.
Pseudomonas aeruginosa is included in the World Health Organization’s Bacterial Priority Pathogen List 2024 because of its concerning ability to acquire and develop high levels of antimicrobial resistance. New-in-class antimicrobial options specifically targeting multidrug-resistant (MDR) P. aeruginosa are lacking.
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.
X-linked sideroblastic anemia (XLSA) is a rare genetic disorder caused by mutations in the ALAS2 gene, which plays a critical role in heme biosynthesis within red blood cells.
Researchers from the Mayo Clinic described the efficacy of NPA-7, a potential first-in-class multivalent fusion protein comprising a sequence of 22 amino acids of human BNP fused to the Mas receptor agonist Ang 1-7.
RSS
